The story of Sildenafil presents a nuanced case for observers read more in the medicinal sector. While initially a blockbuster success, generating vast sums, the patent end and the subsequent arrival of cheaper competitors have significantly affected earnings. This raises questions about the ongoing sustainability of similar drug developments and s